Is there a pill that can make you live to 150?
Short answer: no. There is no pill you can buy or be prescribed today that has been proven to make people live longer — never mind to 150. Some compounds have made mice live longer, and that research is real and worth following. But no one has ever run a study showing a pill extends human life, so anything advertised that way is selling you a mouse result with a human price tag.
No. As of 2026, not a single drug or supplement has been shown in any human trial to extend human lifespan — not to 150, not to 120, not by one year. Every product marketed on that promise is quoting animal research. The compounds with the most serious science behind them (rapamycin, metformin, senolytics including the grape-seed compound PCC1) have all extended lifespan in mice while having no completed human lifespan trial, because such a trial would take decades and none has ever been run to completion. The honest ceiling on today's evidence is healthspan signals over weeks to months in small trials — worth watching, not worth believing headlines about.
- Zero compounds — prescription or over-the-counter — have human trial evidence of lifespan extension. This is not a gap in the marketing; it is a gap in the science, and it applies without exception.
- The "live to 150" claim that went viral in 2026 comes from Lonvi Biosciences and rests on a 2021 mouse study of PCC1, a grape-seed compound. In that study the mice were injected, not given capsules, and treatment began at 24–27 months of age.
- Rapamycin has the strongest animal lifespan record of any drug ever tested, and still has no human lifespan data — the largest human trial to date ran 48 weeks and measured healthspan markers, not survival.
- Metformin's TAME trial was designed to test whether a drug can delay multiple age-related diseases at once in roughly 3,000 older adults. It has not reported results, and until it does, metformin's anti-aging case rests on confounded observational data.
- "Extends lifespan in mice" and "will extend your lifespan" are separated by the single hardest translation problem in all of medicine. Treat any product that blurs them as marketing, not science.
The direct answer, before the nuance
That does not make the field fraudulent. Geroscience — the study of aging as a modifiable process rather than an inevitability — is legitimate, well-funded, and producing results that would have seemed fanciful twenty years ago. Several compounds reliably extend lifespan in mammals. The question is not whether the biology is interesting; it is whether any of it has been shown to work in a person, and the answer to that is still no.
What follows is each headline compound, what species the lifespan claim comes from, and how far it actually is from your medicine cabinet.
The compounds behind the claims, ranked
Ranked on: how close each compound is to human evidence of extended life or healthspan. Animal lifespan results cannot raise a position above C, because no amount of rodent data substitutes for a human trial. Nothing here has commercial placement — several of these are cheap generics nobody profits from.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Rapamycin | Best animal evidence, no human lifespan data | GRADE BPromising |
| 2 | Metformin | Enormous safety record, unproven for aging | GRADE BPromising |
| 3 | Senolytics (dasatinib + quercetin) | Small human trials, biomarker endpoints only | GRADE CEarly |
| 4 | PCC1 (grape-seed procyanidin C1) — the "150" pill | One strong mouse paper, injected not swallowed | GRADE CEarly |
| 5 | NAD⁺ precursors (NMN, NR) | Raises the marker, hasn't moved an outcome | GRADE CEarly |
| 6 | Fisetin | Sold as a senolytic, untested as one in people | GRADE DInsufficient or unsafe |
| 7 | Resveratrol | The cautionary tale of this entire category | GRADE DInsufficient or unsafe |
The most consistently life-extending drug in the history of animal research, reproduced across multiple independent mouse cohorts, including when started in late life. In humans, the largest dedicated healthy-aging trial ran 48 weeks and looked at healthspan measures and safety, not survival. It is a real drug with real immunosuppressive effects and real risks, prescribed off-label for this purpose by a minority of physicians. The animal data justify the research interest; they do not justify a personal protocol without medical supervision.
Decades of use in millions of people with type 2 diabetes give metformin a safety profile almost no other candidate can match, and observational data once suggested diabetics on metformin outlived non-diabetics. That finding is heavily confounded. The TAME trial was designed specifically to settle it — roughly 3,000 older adults, testing whether one drug can delay several age-related diseases at once — and has not reported. Until it does, metformin for aging in a non-diabetic is an informed bet, not a treatment.
The most-cited human senolytic study gave nine people with diabetic kidney disease a short oral course and measured a genuine fall in senescent-cell burden and inflammatory markers. A separate small trial in pulmonary fibrosis reported improved physical function. These are real human signals — and they are also nine-person, biomarker-focused, mostly uncontrolled studies. Dasatinib is a chemotherapy drug, not a supplement.
- 04
PCC1 (grape-seed procyanidin C1) — the "150" pill
GRADE CEarlyOne strong mouse paper, injected not swallowedThe compound behind the 2026 "live to 150" headlines, and the one with the widest gap between what was studied and what is sold. The 2021 Nature Metabolism paper is good science with credible senior authors. But the mice received PCC1 by intraperitoneal injection every two weeks, not as an oral capsule, and the only human data is a 17-person preprint that has not completed peer review. The marketing has run several years ahead of the evidence.
Human randomised trials reliably raise blood NAD⁺ and have shown scattered improvements in walking distance, muscle insulin sensitivity and cholesterol. No trial has run beyond ten weeks, none has measured a disease outcome, and the trials contradict each other on insulin sensitivity. A defensible experiment for someone who understands they are buying a biomarker.
The senolytic most widely sold over the counter, and the one with the least human evidence behind it. No published, adequately powered, placebo-controlled human trial shows clinical benefit at the doses on the shelf, and its human pharmacokinetics are still being characterised — meaning nobody can yet say whether a consumer dose reaches the tissue concentrations that worked in mice.
- 07
Resveratrol
GRADE DInsufficient or unsafeThe cautionary tale of this entire categoryIncluded because it is still sold, and because it is the most instructive failure here. Fifteen years ago it was the compound that was going to extend human life, on the strength of yeast and mouse data and a mechanism story about sirtuins. Human trials consistently failed to reproduce the effects, bioavailability turned out to be poor, and the original mechanism did not hold up. Every compound above is currently at the stage resveratrol was at in 2010.
What the headline said, and what the study did
The 2026 "live to 150" claim, audited
| The claim | What the underlying research actually shows |
|---|---|
| "A pill that could let you live to 150" | A compound that extended lifespan in mice by 9.4%. No human has ever taken it in a completed, peer-reviewed lifespan or healthspan trial. |
| "Extends life by 64%" | This is the increase in median lifespan remaining after treatment began, in mice already aged 24–27 months. The overall lifespan increase in the same animals was 9.4%. The larger number is the more impressive-sounding way to describe the smaller result. |
| "A capsule you take orally" | The mice received the compound by intraperitoneal injection — into the abdominal cavity — once every two weeks at 20 mg/kg. Oral absorption of a capsule is a different pharmacological question that the lifespan study did not test. |
| "Clinically proven to clear zombie cells" | Senescent-cell clearance was demonstrated in mice and cell culture. The only human data is an unpublished 17-person preprint reporting changes in senescence markers over three days — not a clinical outcome, not peer-reviewed, not controlled. |
| "Living to 150 will be reality in a few years" | The verified human lifespan record is 122 years, set in 1997 and not since approached. No intervention of any kind has been shown to move the ceiling in humans. |
What actually extends healthy human life, today
This is the part that gets left out of the 150 stories, and it is the only part with the evidence quality the rest of this page demands. The interventions with genuine, replicated human outcome data are unglamorous and largely unpatentable: not smoking, maintaining muscle mass and cardiorespiratory fitness, treating blood pressure and lipids when they are high, sleeping adequately, and staying socially connected. None of these will take anyone to 150. All of them have better evidence than every compound in the ranking above, combined.
That is not a reason to dismiss geroscience. It is a reason to keep the pill research in its proper place: a promising field that may eventually add something on top of the basics, not a replacement for them. Anyone selling the pill as a substitute for the basics is selling the one thing this field has never demonstrated.
If you are considering one of these compounds anyway
- Screen for interactions first. The most common real-world harm in this category is not the compound — it is the compound alongside a prescription you already take. This is the question a pharmacist would start with, and the one most people skip.
- Check the dose against the trial, not the label. Several products cite a study while containing a fraction of the dose that study used, which means the evidence does not transfer even if the study was sound.
- Check the route of administration against the trial. PCC1 is the clearest example on this page: an injected result does not automatically become an oral one.
- Treat anything sold with a specific lifespan number as a red flag. No honest reading of this evidence base supports a number, and a company confident enough to name one is telling you something about its standards.
Frequently asked questions
Are there clinically proven pills to delay biological aging?
No pill has been proven in an adequately powered human trial to delay biological aging in a way that changes a clinical outcome. Several compounds shift biomarkers — NAD⁺ levels, senescence markers, methylation-clock readings — over weeks to months in small trials. A biomarker moving is not the same as aging slowing, and no product has closed that gap. The honest answer to this question in 2026 is: not yet.
What is the safest pill to drastically slow aging?
No pill has been shown to drastically slow aging at all, so the question has no safe answer in the form it is usually asked. Of the compounds being studied, metformin has by far the largest human safety record — decades of use in millions of people — but it has not been shown to slow aging in anyone without diabetes, and the trial designed to test that has not reported. The safest option with proven benefit remains the unglamorous one: the things that improve cardiovascular and metabolic health, which have outcome data no supplement in this category can approach.
Which longevity pills show strongest evidence for life extension?
In animals, rapamycin has the strongest and most replicated lifespan evidence of any compound ever tested. In humans, nothing does — no compound has human life-extension evidence, because no completed trial has ever measured it. If you rank strictly on human data rather than animal data, the list is empty, and any source giving you a confident top pick is ranking on mouse studies or on marketing.
Can any supplement stack realistically extend lifespan past normal?
There is no evidence that any combination of supplements extends human lifespan, and stacking increases interaction risk and cost while the evidence behind each additional item usually weakens. Combining compounds also multiplies the unknowns: the trials that exist tested single agents, so a stack has less evidence behind it than its individual parts, not more. A short list of well-evidenced compounds at studied doses is a more defensible position than a long list of plausible ones.
Is the grape seed pill that claims to extend life to 150 legitimate?
The underlying science is legitimate; the 150 claim is not. PCC1 is a real compound, the 2021 mouse study was published in Nature Metabolism with credible senior authors including Judith Campisi and James Kirkland, and senescent-cell clearance is a serious research avenue. But the mice were injected rather than given capsules, treatment started in old age, the overall lifespan gain was 9.4%, and there is no completed peer-reviewed human trial. A company translating that into "150 years" is making a marketing claim its own evidence does not support.
How do common metabolic drugs impact aging biology?
Metformin, SGLT2 inhibitors and GLP-1 agonists all act on nutrient-sensing and metabolic pathways that overlap with the pathways implicated in aging, which is why they keep appearing in geroscience discussions. The overlap is real and mechanistically interesting. What has not been established is that taking them without the metabolic condition they treat produces a net benefit in a healthy person — that is precisely the question TAME was designed to answer for metformin, and it has not reported.
What should I ask a doctor about anti-aging medications?
Four questions cover most of it: what does this drug have in humans rather than animals, and for what outcome; how does it interact with everything I already take; what would we monitor, and what result would make us stop; and what is the cheapest intervention with better evidence that I am not already doing. The fourth question is the one that most often changes the answer, and the one least likely to be volunteered by a clinic selling a protocol.
Keep reading
- PCC1 and the grape-seed longevity pill: what the study actually showed
The full breakdown of the mouse trial behind the 150 headlines, including the injection-versus-capsule problem.
- Senolytic supplements and drugs: what actually has human data
The wider senolytic category, graded on human trials rather than mechanism.
- Rapamycin for longevity: what the evidence actually shows
The compound with the best animal lifespan record, and its human evidence gap.
- What are the most effective antiaging prescription treatments available?
The prescription side, ranked on human evidence.
- The best longevity supplements, ranked by human evidence
If the question is what to actually take, start here instead.
- How we grade evidence
The criteria behind every position in this ranking.
More in Anti-aging pharma
- Rapamycin for longevity: what the human evidence actually shows
The only 48-week human trial (PEARL, n=129) missed its primary endpoint. What rapamycin has actually shown, the real risks, and who should never take it.
- What are the most effective antiaging prescription treatments available?
Tretinoin, botulinum toxin and statins rank on randomised evidence above rapamycin, metformin and senolytics, which lack trial evidence for anti-ageing use.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
Botulinum toxin has the largest measured effect on dynamic wrinkles in randomised trials, ahead of tretinoin for photoaging and fillers for static folds.
- What antiaging pharmaceuticals work best for skin rejuvenation?
Tretinoin ranks first for skin rejuvenation, improving texture, fine wrinkles, and pigmentation in decades of trials, ahead of hydroquinone and Botox.
- Which doctor-prescribed antiaging drugs are safest long term?
Statins and antihypertensives top the safety ranking with 30-plus years of data; growth hormone and testosterone 'optimisation' rank lowest, with real harm.
- How do I choose a medical-grade antiaging treatment plan?
A medical-grade anti-ageing plan measures first — blood pressure, ApoB, HbA1c — then treats only what's abnormal with on-label, proven drugs, and monitors.